Our partners

COORDINATOR

COUNTRY

MetrioPharm

To website

Switzerland

WORK PACKAGES

WP1 – Clinical COVID-19 Phase IIa trial 
WP2 – Viral Variants
WP3 – IMP & API Scale-up
WP5 – Stakeholder engagement, Dissemination, Exploitation & Communication 
WP6 – Project Management

TEAM

MetrioPharm AG is the developer of MP1032 and based in Switzerland. MetrioPharm is a clinical-stage development company focused on therapies for acute and chronic inflammatory diseases. The team has extensive experience in preclinical and clinical development.

Dr. Wolfgang Brysch, (he/him), Co-founder of MetrioPharm

Dr. Wolfgang Brysch is a co-founder of MetrioPharm and served as Chief Executive Officer until 2021. Now he focuses on expanding the company’s medical pipeline as Chief Scientific Officer and Chief Medical Officer. Until 2014, he was managing director of BioMedion – a successful IT company, specializing in pharmaceutical software services. Prior to this, he worked as managing director and Chief Scientific Officer at Biognostik GmbH. At that time, he was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, he headed a research group for molecular neurobiology and cancer research at the Max-Planck-Institute Göttingen. He has extensive experience in drug  development.

Within the iMPact project MetrioPharm is responsible for Phase IIa clinical trial and upscaling GMP production process of MP1032 API for future widespread use.

Dr. Astrid Kaiser, (she/her), Head of Drug Development at MetrioPharm.

Dr. Astrid Kaiser is Head of Drug Development at MetrioPharm since 2015. Prior to that, she was senior project manager of the MP1000 drug development. From 2004 to 2008, Dr. Kaiser worked for Jerini AG as a research and development consultant. Before, she was a senior project manager for preclinical model development and consulted biotech and pharmaceutical companies in research and development. Until 1999, she worked as a senior scientist in human cancer research at Benjamin Franklin University Hospital. Her area of expertise is inflammatory diseases, oncology and molecular biology. She has many years of experience in drug development, GMP manufacturing of API and IMP, GLP toxicology studies and clinical studies.

Within the iMPact project MetrioPharm is responsible for Phase IIa clinical trial and upscaling GMP production process of MP1032 API for future widespread use.

PARTNER

COUNTRY

ImmunoLogik

To website

Germany

WORK PACKAGES

WP2 – Viral Variants
WP5 – Stakeholder engagement, Dissemination, Exploitation & Communication 
WP6 – Project Management

TEAM

The ImmunoLogik GmbH is a German SME with expertise in anti-viral drug efficacy testing. Their role in the project will be to investigate the efficacy of MP1032 in different virus variants.

Dr. Christian Setz, (he/him), Scientific Managing Director of ImmunoLogik

Dr. Christian Setz is the Scientific Managing Director of ImmunoLogik since 2017. He has more than 17 years of experience in virology and was the project leader of an independent HIV-1 research group at the Institute for Clinical and Molecular Virology in Erlangen. His scientific work has been published in leading international science journals and he participated in numerous renowned national and international virology congresses. In particular, he has extenstensive research experience in the development of novel antiretroviral strategies by deciphering molecular mechanisms, which regulate the functions of viral proteins and their cellular counterparts. He is also the co-inventor of ImmunoLogik’s lead candidates IML-106 and IML-206.

Within the iMPact project ImmunoLogik is responsible for preclinical studies to validate the efficacy of the project’s lead candidate against other SARS-CoV-2 variants.

PARTNER

COUNTRY

PHOX Consulting

To website

Austria

WORK PACKAGES

WP4 – Regulatory strategy
WP5 – Project Management

TEAM

PHOX Consulting, an SME from Austria, is specialized in consultancy services throughout nonclinical development of drugs and medical devices and will ensure regulatory compliance of the study and development of a regulatory strategy to include children and pregnant women in future clinical use of MP1032 in COVID-19. Phox will also be responsible for early contact with the EMA after the project is granted.

Volker Blust, (he/him), Founder of PHOX Consulting 

Volker Blust is the founder of PHOX consulting, which started in 2021. In 2013 he joined MC Toxicology consulting to work on drug screening candidates pertaining to small molecules, herbals, biologics, and vaccines. Furthermore, he contributed to the successful development of substance-based medical devices and implants. During his work as a senior consultant he has authored respective sections in various regulatory documents (CTDs, INDs, Briefing Documents, and IBs), biocompatibility reports, toxicological risk assessments and PDE calculations.  

Within the iMPact project PHOX Consulting is responsible for the development of post Phase II regulatory strategy to ensure MP1032 is ready for Phase IIb/III clinical studies and market approval. 

PARTNER

COUNTRY

Catalyze Group

To website

Netherlands

WORK PACKAGES

WP5 – Stakeholder engagement, Dissemination, Exploitation & Communication 
WP6 – Project Management

TEAM

Catalyze is a Dutch company specialized in strategic consulting services, funding consultancy, project management and more and provides expertise for all development stages. Catalyze will be responsible for project management as well as dissemination and communication of the project results.

Donna van Dommelen (she/her), Project Manager at Catalyze

Donna van Dommelen graduated with an Msc in Management, Policy and Entrepreneurship in Health and Life Sciences. Her background includes coordination and management of life science research and she has extensive experience in managing EU Horizon projects. Her current portfolio includes a diverse set of projects, from medical diagnostics to therepeutics, and sustainability focused projects. The projects are within a wide-vairety of academic and industrial settings and differ from smaller single applicant projects to larger multi-parnter projects.

Within the iMPact project, she responsible for the management, planning and monitoring of the project, and ensuring that the (financial) reporting is in line with the regulations set out in the Grant Agreement.

Frederike Schmitz (she/her), Senior Science Communication Advisor at Catalyze

Frederike Schmitz graduated with a master’s in nutrition science and received a PhD in Immunology. She has extensive experience in science communication, ranging from scientific and medical writing to writing and illustrating scientific content targeted towards lay audiences.

Within Catalyze she is overseeing the strategy and tasks of science communication and dissemination within several EU Horizon projects.

Christopher Kruger (he/him), Science Communication Officer at Catalyze

Christopher Kruger graduated with an Msc in Human Movement Sciences in 2021. His background encompasses various dissemination activities ranging from social media planning, grant proposals, and systematic reviews to presentations.

Within the iMPact project, he is responsible for planning and undertaking dissemination and communication activities.